Explore
Trendline
Johnson Johnson Consumer Health Unit Kenvue Prices IPO at $22 Per Share, Marking Largest U.S. IPO Since 2021
Johnson Johnson Consumer Health Unit Kenvue Prices IPO at $22 Per Share, Marking Largest U.S. IPO Since 2021
Read More
Trendline
Intercontinental Exchange (ICE) Reports Strong Revenue Growth Amidst Stock Decline, Raising Rebound Questions
Intercontinental Exchange (ICE) Reports Strong Revenue Growth Amidst Stock Decline, Raising Rebound Questions
Read More
Trendline
Gilead Sciences Achieves New All-Time Highs Driven by Strong HIV and Liver Disease Portfolio Growth
Gilead Sciences Achieves New All-Time Highs Driven by Strong HIV and Liver Disease Portfolio Growth
Read More
Trendline
Humana Stock Plummets 13% Following Federal Proposal on Medicare Advantage Overpayments
Humana Stock Plummets 13% Following Federal Proposal on Medicare Advantage Overpayments
Read More
Trendline
Kimberly-Clark Stock Rises Amid Improved Analyst Sentiment and Kenvue Acquisition Synergy Focus
Kimberly-Clark Stock Rises Amid Improved Analyst Sentiment and Kenvue Acquisition Synergy Focus
Read More
Trendline
UnitedHealth Group Stock Rises Following TD Cowen Upgrade Amid Global Market Retreat
UnitedHealth Group Stock Rises Following TD Cowen Upgrade Amid Global Market Retreat
Read More
Trendline
Cardinal Health Faces DOJ Investigations Amidst Strong Financial Performance and Market Risks
Cardinal Health Faces DOJ Investigations Amidst Strong Financial Performance and Market Risks
Read More
Trendline
T. Rowe Price Group Reports Strong Q3 2026 Earnings Amidst Market Underperformance
T. Rowe Price Group Reports Strong Q3 2026 Earnings Amidst Market Underperformance
Read More
Trendline
Moderna Raises 2026 Revenue Growth Outlook Amidst Personalized Cancer Vaccine Program Success and New Flu Vaccine Approval
Moderna Raises 2026 Revenue Growth Outlook Amidst Personalized Cancer Vaccine Program Success and New Flu Vaccine Approval
Read More
Trendline
CRISPR Therapeutics Stock Could Be Undervalued Despite Recent Data, Analysts Suggest
CRISPR Therapeutics Stock Could Be Undervalued Despite Recent Data, Analysts Suggest
Read More
Trendline
Pfizer's New Drug Revenue Surges 32% in Q3 2026 Amidst Patent Cliff Concerns
Pfizer's New Drug Revenue Surges 32% in Q3 2026 Amidst Patent Cliff Concerns
Read More
Trendline
D.R. Horton Stock Declines Amid Housing Affordability and Demand Concerns
D.R. Horton Stock Declines Amid Housing Affordability and Demand Concerns
Read More